Full-Time
Develops cell therapy for chronic kidney disease
No salary listed
Entry, Junior
Winston-Salem, NC, USA
ProKidney focuses on treating Chronic Kidney Disease (CKD) through a unique cell therapy called rilparencel. This therapy aims to preserve kidney function in patients with advanced CKD, potentially delaying or eliminating the need for dialysis, which many patients currently rely on. ProKidney targets a significant healthcare issue, as over 35 million adults in the U.S. are affected by CKD, with many progressing to dialysis each year. The company is in the late stages of clinical trials for rilparencel, which has shown promise in maintaining kidney function. Unlike competitors, ProKidney is dedicated to a specific and underserved segment of the healthcare market, focusing solely on CKD treatment. The goal is to provide a viable alternative to dialysis, improving the quality of life for millions of patients.
Company Size
201-500
Company Stage
IPO
Headquarters
Winston-Salem, North Carolina
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) - ProKidney Corp. (Nasdaq: PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference.
In June 2023, ProKidney announced that the company planned to invest $485 million in a Greensboro biomedical factory that would create roughly 330 jobs - with those jobs averaging just under $75,000 a year.
ProKidney's purchasing the buildings from Breit SE Industrial Propco, also known as Blackstone Real Estate Income Trust.
ProKidney had previously planned to expand operations into Greensboro.
Less than six months after joining the company, Dr. Bruce Culleton was appointed CEO of ProKidney, a regenerative medicine that made one of the largest manufacturing investments in Triad history.